儿童急性白血病的肠道微生物组:从易感到治愈
该综述聚焦儿童急性白血病(AL)患者的肠道微生物组(GM),梳理从白血病易感到治疗及存活期的时序变化。文章指出特定GM配置可能参与白血病发生,治疗期间GM改变与并发症相关,尤其在造血干细胞移植中,且GM扰动可持续至存活期。
要点
- 特定肠道微生物组配置可能参与儿童急性白血病的多步骤发生假说。
- 急性白血病治疗期间肠道微生物组改变与治疗相关并发症相关,尤其在造血干细胞移植中。
- 即使去除抗生素、化疗药或同种免疫反应等修饰因素,肠道微生物组扰动仍可持续至存活期。
核心结论
- 肠道微生物组在儿童急性白血病的易感、治疗并发症及存活期健康问题中可能发挥重要作用。
研究设计与样本
- 综述性文章,旨在全面回顾儿童急性白血病患者肠道微生物组从易感到治愈的时序变化。
主要发现
- 特定肠道微生物组配置可能参与儿童急性白血病的多步骤发生假说。
- 急性白血病治疗期间肠道微生物组发生改变,并与治疗相关并发症相关,尤其在造血干细胞移植期间。
- 肠道微生物组扰动在去除抗生素、化疗药物或同种免疫反应等修饰因素后仍可能持续,并促成存活者的多种健康问题。
临床怎么用
- 文章强调针对肠道微生物组的潜在干预,以促使其转向可能促进健康的配置。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The gut microbiome (GM) has emerged as a key factor in the genesis and progression of many diseases. The intestinal bacterial composition also influences treatment-related side effects and even the efficacy of oncological therapies. Acute leukemia (AL) is the most common cancer among children and the most frequent cause of cancer-related death during childhood. Outcomes have improved considerably over the past 4 decades, with the current long-term survival for acute lymphoblastic leukemia being ∼90%. However, several acute toxicities and long-term sequelae are associated with the multimodal therapy protocols applied in these patients. Specific GM configurations could contribute to the multistep developmental hypothesis for leukemogenesis. Moreover, GM alterations occur during the AL therapeutic course and are associated with treatment-related complications, especially during hematopoietic stem cell transplantation. The GM perturbation could last even after the removal of microbiome-modifying factors, like antibiotics, chemotherapeutic drugs, or alloimmune reactions, contributing to several health-related issues in AL survivors. The purpose of this article is to provide a comprehensive review of the chronological changes of GM in children with AL, from predisposition to cure. The underpinning biological processes and the potential interventions to modulate the GM toward a potentially health-promoting configuration are also highlighted.
引用
- Masetti R, Muratore E, Leardini D, et al. Gut microbiome in pediatric acute leukemia: from predisposition to cure. Blood Adv. 2021. PMID: 34610115. doi:10.1182/bloodadvances.2021005129
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。